The Pharmaceutical Journal
Vol 280 No 7498 p469
19 April 2008

This article
Reprint   Photocopy

PDF 40K, Acrobat Reader

Products

Accessing SPCs
The summaries of product characteristics and patient information leaflets for medicines licensed in the UK are available online

SPC changes
• Femara

SPC changes

Femara
Following standard adjuvant tamoxifen therapy, treatment with Femara (letrozole; Novartis) should continue for four years or until tumour relapse occurs, Femara’s summary of product characteristics now states.

Back to Top